Neumedicines Incis An Emerging Therapeutic Biotechnology Company Focused On Developing And Commercializing Innovative And Proprietary Products And Approaches That Address Unmet Clinical And Societal Needs In The Areas Of Oncologyhematologyand Immunologythe Company Operates From Its Headquarters In Pasadenacalifornia Neumedicineslead Product Candidate Is Recombinant Human Interleukin 12Rhuil 12 A Heterodimeric Glycoprotein And Cytokinerhuil 12 Is Being Developed Under The Trade Name Hemamaxa C For Various Clinical Indicationsincluding Hematopoietic Syndrome Of Acute Radiation Syndromehsars Skin Cancers And Other Solid Tumorsand Blood Disorders And Malignancies
No conferences found for this company.
| Company Name | Neumedicines Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
